Выбрать главу

Georges was careful to outwardly live on his Interpol salary, but pragmatic enough to dip into the Switzerland account to pay for his son’s education. There was a healthy amount in the account now, having accumulated for ten years and drawn interest as well. The money was there; he wouldn’t use it to buy luxuries for himself, but he would use it for his family. Eventually, he knew, he would have to do something with the money, but he didn’t know what.

Over the years he had dealt mostly with Rodrigo Nervi, Salvatore’s heir apparent, and now heir in fact. He would almost rather have dealt with Salvatore. Rodrigo was colder than Salvatore, smarter, and, Georges thought, probably more ruthless. The only advantage Salvatore had had over his son was experience, and more years in which to accumulate a devil’s list of sins.

Georges checked the time: one pm. With the six hours’ time difference between Paris and Washington, that made it seven AM there, just the right time for reaching someone on a cell phone.

He used his own cellular phone, not wanting a record of the call on Interpol’s records. Marvelous inventions, cell phones; they made pay phones almost obsolete. They weren’t as anonymous, of course, but his was secure against eavesdropping and far more convenient.

“Hello,” a man said after the second ring. In the background Georges could hear a television, the modulated tones of newscasters.

“I’ll be sending you a photograph,” Georges said. “Would you please run it through your facial-recognition program as soon as possible?” He never used a name, and neither did the other man. Whenever one of them needed information, he would call on a personal phone, rather than going through channels, which kept their official contact at a minimum.

“Sure thing.”

“Please send all pertinent information to me by the usual channel.”

They each rang off; conversations were always kept to a minimum as well. Georges knew nothing about his contact, not even his name. For all he knew, his counterpart in Washington cooperated for the same reason he himself did, out of fear. There was never any hint of friendliness between them. This was business, which they understood all too well.

“I need a definite answer. Will you have the vaccine ready by the next influenza season?” Rodrigo asked Dr. Giordano. There was a huge report on Rodrigo’s desk, but he was concerned with the bottom line, and that was whether the vaccine could be produced in the volume needed, before it was needed.

Dr. Giordano had a hefty grant from several world health organizations to develop a reliable vaccination against avian influenza. Theirs wasn’t the only laboratory working on this problem, but it was the only one that had Dr. Giordano. Vincenzo had become fascinated with viruses and had left his private practice behind for a chance to study them, becoming an acknowledged expert and seen as someone who was either a remarkable genius or remarkably lucky in working with the microscopic nasties.

A vaccine for any strain of avian flu was difficult to develop, because avian flu was fatal to birds and vaccines were made by growing the influenza virus in eggs. Avian flu, however, killed the eggs; therefore, no vaccine. The developer of a process for producing an effective, reliable vaccine against avian flu would have a huge cash cow.

This was, potentially, the biggest moneymaker in the entire Nervi corporate structure, more lucrative even than opiates. So far avian flu itself was following dead-end paths: The virus would pass from an infected bird to a human, but it lacked the means of human-to-human infection. The human host would either die or get well, but without infecting anyone else. Avian flu, as it was now, was still incapable of causing an epidemic, but the American CDC and the World Health Organization were greatly alarmed by certain changes in the virus. The experts were betting that the next influenza pandemic, the influenza virus against which humans had no immunity because they’d never come in contact with it before, would be an avian influenza virus—and they were holding their breaths with each successive flu season. So far, the world had been lucky.

If the virus made the necessary genetic changes that would enable it to jump from human to human, the company that could make a vaccine for that influenza would be able to name its price.

Dr. Giordano sighed. “If there are no more setbacks, the vaccine can be ready by the end of next summer. I cannot, however, guarantee there will be no more setbacks.”

The explosion in the lab last August had destroyed several years of work. Vincenzo had isolated a recombinant avian virus and painstakingly developed a means of producing a reliable vaccine. The explosion had not only destroyed the product, it had also taken out a huge amount of information. Computers, files, hard copy notes—gone. Vincenzo had started again from scratch.

The process was going faster this time, because Vincenzo knew more about what worked and what didn’t, but Rodrigo was concerned. This season’s influenza was of the ordinary variety, but what about next season? Producing a batch of vaccine took about six months, and a large quantity of it had to be ready by the end of next summer. If they missed that deadline and next season the avian virus made the genetic mutation it needed to jump from human to human, they would have missed the opportunity to make an incredible fortune. The infection would flash around the world, millions would die, but in that one season the immune systems of those who survived would adjust and that particular virus would reach the end of its brief success. The company that was ready with a vaccine when the virus mutated was the company that would reap the benefits.

They might be lucky once again, and the avian virus wouldn’t mutate in time for the next influenza season, but Rodrigo refused to rely on luck. The mutation could happen at any time. He was in a race with the virus, and he was determined to win.

“It’s your job to make certain there aren’t any more setbacks,” he told Vincenzo. “An opportunity such as this comes once in a lifetime. We will not miss it.” Left unsaid was that if Vincenzo couldn’t get the work done, Rodrigo would bring in someone who could. Vincenzo was an old friend, yes—of his father’s. Rodrigo wasn’t burdened by the same sentimentality. Vincenzo had done the most important work, but it was at a point where others could take over.

“Perhaps it isn’t once in a lifetime,” said Vincenzo. “What I have done with this virus, I can do again.”

“But in these particular circumstances? This is perfect. If all goes well, no one will ever know and, in fact, we’ll be praised as saviors. We’re perfectly positioned to take advantage this one time. With the WHO funding your research, no one will be amazed that we have the vaccine. But if we go to the well too many times, my friend, the water will become muddied and questions will be asked that we don’t want answered. There cannot be a pandemic every year, or even every five years, without someone becoming suspicious.”

“Things change,” Vincenzo argued. “The world’s population is living in closer contact with animals than ever before.”

“And no disease has ever been studied as thoroughly as influenza. Any variation is examined by thousands of microscopes. You’re a doctor, you know this.” Influenza was the great killer; more people had died in the 1918 pandemic than during the four-year Great Plague that had devastated Europe during the Middle Ages. The 1918 influenza had killed, it was estimated, between forty and fifty million people. Even in normal years influenza killed thousands, hundreds of thousands. Every year two hundred and fifty million doses of vaccine were produced, and that was only a fraction of what would be needed during a pandemic.

Labs in the United States, Australia, and the U.K. worked under strict regulations to produce the vaccine that targeted the virus researchers said would most likely be dominant in each influenza season. The thing about a pandemic, however, was that it was always caused by a virus that hadn’t been predicted, hadn’t been seen before, and thus the available vaccine wouldn’t be effective against it. The whole process was a giant guessing game, with millions of lives at stake. Most of the time, the researchers guessed right. But about once every thirty years or so, a virus would mutate and catch them flat-footed. It had been thirty-five years since the Hong Kong influenza pandemic of 1968–69; the next pandemic was overdue, and the clock was ticking.